Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $102

Benzinga Newsdesk www.benzinga.com Positive 87.3%

Neg 0% Neu 0% Pos 87.3%

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $102.